SHYNDEC(SH:600420)2024-07-08 08:56Financial Performance - The company expects a net profit attributable to shareholders of 688 million to 748 million CNY for the first half of 2024, representing a year-on-year growth of 99.42% to 116.81%[2] - The net profit attributable to shareholders after deducting non-recurring gains and losses is projected to be 655 million to 715 million CNY, reflecting a growth of 103.42% to 122.05% compared to the same period last year[3] - The net profit for the same period last year was 344.94 million CNY, with a total profit of 617.56 million CNY[7] Operational Efficiency - The company has actively seized market opportunities, leading to an increase in sales of high-margin products[5] - Cost reduction and efficiency improvement measures have been implemented, resulting in a decrease in production costs year-on-year[6] - The company has significantly reduced period expenses, enhancing management efficiency[9] Risk Factors - The performance forecast is based on preliminary calculations by the finance department and has not been audited by an accounting firm[10] - The company warns of potential risks due to market supply and demand fluctuations in antibiotic intermediates and raw materials, as well as the impact of industry policies[6]